


INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6613-66749-01
		Application Number	10/658,971
		Filing Date	September 9, 2003
		First Named Inventor	David Jonathan Madge
		Art Unit	1615
		Examiner Name	To be assigned
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS	
BK		Bastin et al., "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities," <i>Organic Process Research & Development</i> 4:427-235, 2000	
		Brikh et al., "Boronated thiophenols: a preparation of 4-mercaptophenylboronic acid and derivatives," <i>Journal of Organometallic Chemistry</i> 581:82-86, 1999	
		Davies et al., "Peroxides of Elements other than Carbon. Part XII. The Autoxidation of Optically Active 1-Phenylethylboronic Acid," <i>J Chem Soc</i> pp. 17-22, 1967	
		Elgendy et al., "Design of a novel class of bifunctional thrombin inhibitors, synthesised by the first application of peptide boronates of solid phase chemistry," <i>Tetrahedron Letters</i> 38(18):3305-3308, 1997	
		Hsiao et al., "A Facile Synthesis of <i>tert</i> -Butyl 2-[Benzyloxycarbonyl]amino]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propionate: An Orthogonally Protected Boronic Acid Analog of Aspartic Acid," <i>Synthesis</i> 7:1043-1046, 1998	
		Kettner et al., "Inhibition of the Serine Proteases Leukocyte Elastase, Pancreatic Elastase, Cathepsin G, and Chymotrypsin by Peptide Boronic Acids," <i>The Journal of Biological Chemistry</i> 259(24):15106-15114, 1984	
		Kettner et al., "The Selective Inhibition of Thrombin of Peptides of Boroarginine," <i>The Journal of Biological Chemistry</i> 265(30):18289-18297, 1990	
		Lappert, "Organic Compounds of Boron," <i>Chem. Review</i> 56:959-1064, 1956	
		Martichonok et al., "Cysteine Proteases such as Papain are not Inhibited by Substrate Analogue Peptidyl Boronic Acids," <i>Bioorganic and Medicinal Chemistry</i> 5(4):679-684, 1997	
		Skordalakes et al., "Crystallographic Structures of Human α -Thrombin Complexed to Peptide Boronic Acids Lacking a Positive Charge of P1. Evidence of Novel Interactions," <i>J. Am. Chem. Soc.</i> 119:9935-9936, 1997	
		Snyder et al., "Organoboron Compounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids," <i>Am Chem Soc</i> 60:105-111, 1938	
		Snyder et al., "Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes," <i>Am Chem Soc</i> 80:3611-3615, 1958	
↓		Wityak et al., "Synthesis of Thrombin Inhibitor DuP 714," <i>J. Org. Chem.</i> 60:3717-3722, 1995	

EXAMINER SIGNATURE:	/Brian-Yong Kwon/	DATE CONSIDERED:	07/12/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6613-66749-01
Application Number	10/658,971
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1615
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
BK		US-2004-0147453-A1	29 July 2004	Deadman et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	

EXAMINER SIGNATURE: /Brian-Yong Kwon/	DATE CONSIDERED: 07/12/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6613-66749-01
Application Number	10/658,971
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1615
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
BK		Davies, <i>The Pharmaceutical Journal</i> 266:322-323, 2001

EXAMINER
SIGNATURE: /Brian-Yong Kwon/

DATE
CONSIDERED: 07/12/2006

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

WK:jam 08/20/03 6613-66749-01 301624
 AUG 23 2004
 PATENT & TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT
 BY APPLICANT**

Attorney Docket Number	6613-66749-01
Application Number	10/658,971
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1615
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
BK		6,083,903	04 July 2000	Adams et al.
↓		6,297,217	02 Oct 2001	Adams et al.
		6,617,317	09 Sept 2003	Adams et al.
		6,713,446	30 Mar 2004	Gupta et al.
		6,747,150	08 June 2004	Adams et al.

EXAMINER SIGNATURE:	/Brian-Yong Kwon/	DATE CONSIDERED:	07/12/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6613-66749
Application Number	10/658,971
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1615
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
BK		WIPO/PCT	WO 96/12499	02 May 1996	The DuPont Merck Pharmaceutical Company


OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	

EXAMINER SIGNATURE: /Brian-Yong Kwon/

DATE CONSIDERED: 07/12/2006

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6613-66749
Application Number	10/658,971
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1615
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
BK		4,499,082	12 Feb 1985	Shenvi et al.
		4,701,545	20 Oct 1987	Matteson et al.
		4,935,493	19 Jun 1990	Bachovchin et al.
		4,963,655	16 Oct 1990	Kinder et al.
		5,187,157	16 Feb 1993	Kettner et al.
		5,444,049	22 Aug 1995	de Nanteuil et al.
		5,462,964	31 Oct 1995	Fevig et al.
		5,563,127	08 Oct 1996	Amparo et al.
		5,574,014	12 Nov 1996	Claeson et al.
		5,585,360	17 Dec 1996	de Nanteuil et al.
		5,658,885	19 Aug 1997	Lee et al.
		5,681,978	28 Oct 1997	Matteson et al.
		5,731,439	24 Mar 1998	Carini et al.
		5,780,454	14 Jul 1998	Adams et al.
		5,814,622	29 Sep 1998	de Nanteuil et al.
		6,066,730	23 May 2000	Adams et al.
		6,313,096	06 Nov 2001	Claeson et al.

EXAMINER SIGNATURE: /Brian-Yong Kwon/

DATE CONSIDERED: 07/12/2006




* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Attorney Docket Number		6613-66749
				Application Number		10/658,971
				Filing Date		September 9, 2003
				First Named Inventor		David Jonathan Madge
				Art Unit		1615
				Examiner Name		To be assigned
		6,465,433	15 Oct 2002	Adams et al.		

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
BK		0471651	19 Feb 1992	EPC
		WO 92/07869	14 May 1992	WIPO/PCT
		WO 94/21650	29 Sep 1994	WIPO/PCT
		WO 94/25049	10 Nov 1994	WIPO/PCT
		WO 95/09634	13 Apr 1995	WIPO/PCT
		WO 95/09858	13 Apr 1995	WIPO/PCT
		WO 95/09859	13 Apr 1995	WIPO/PCT
		WO 96/13266	09 May 1996	WIPO/PCT
		WO 96/20689	11 Jul 1996	WIPO/PCT
		WO 97/05161	13 Feb 1997	WIPO/PCT
		WO 98/31688	23 Jul 1998	WIPO/PCT
		WO 99/26652	03 Jun 1999	WIPO/PCT
		WO 00/35904	22 Jun 2000	WIPO/PCT
		WO 00/35905	22 Jun 2000	WIPO/PCT
		WO 00/41715	20 Jul 2000	WIPO/PCT
↓		WO 01/41796	14 Jun 2001	WIPO/PCT

EXAMINER SIGNATURE: /Brian-Yong Kwon/		DATE CONSIDERED: 07/12/2006	
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			


INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Attorney Docket Number	6613-66749
				Application Number	10/658,971
				Filing Date	September 9, 2003
				First Named Inventor	David Jonathan Madge
				Art Unit	1615
				Examiner Name	To be assigned
BK		WO 01/02424	11 Jan 2001	WIPO/PCT	
		WO 02/36157	10 May 2002	PCT	
		WO 02/059130	01 Aug 2002	WIPO/PCT	
		WO 02/059131	01 Aug 2002	WIPO/PCT	
		WO 03/007984	30 Jan 2003	WIPO/PCT	
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS			
BK		Claeson et al., <i>Thromb Haemostas</i> , Vol. 65, p. 1289, 1991.			
		Claeson et al., "Novel peptide mimetics as highly efficient inhibitors of thrombin based on modified D-Phe-Pro-Arg sequences," in <i>Peptides, Chemistry and Biology</i> , Smith J A, Rivier J E, Eds., <i>Escom: Leiden</i> pp. 824-825, 1992.			
		Claeson et al., <i>Biochem J.</i> 290:309-312, 1993.			
		Claeson et al., <i>The Design of Synthetic Inhibitors of Thrombin</i> 340:83-89, 1993.			
		Claeson, <i>Blood Coagulation and Fibrinolysis</i> 5:411-436, 1994.			
		Coburn, <i>Exp. Opin. Ther. Patents</i> 11(5):721-738, 2001.			
		Contreras et al., <i>J. Org. Chem.</i> 246:213-217, 1983.			
		Deadman et al., <i>J. Medicinal Chemistry</i> 38:1511-1522, 1995.			
		Deadman et al., <i>J. Enzyme Inhibition</i> 9:29-41, 1995.			
		Elgendy et al., <i>Thromb Haemostas</i> 65:775, 1991.			
		Elgendy et al., <i>Tetrahedron Letters</i> 33(29):4209-4212, 1992.			
		Elgendy et al., <i>The Design of Synthetic Inhibitors of Thrombin</i> 340:173-178, 1993.			
		Elgendy et al., <i>Tetrahedron</i> 50(12):3803-3812, 1994.			
EXAMINER SIGNATURE: /Brian-Yong Kwon/			DATE CONSIDERED: 07/12/2006		
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.					

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6613-66749
		Application Number	10/658,971
		Filing Date	September 9, 2003
		First Named Inventor	David Jonathan Madge
		Art Unit	1615
		Examiner Name	To be assigned
BK		Esmail et al., <i>Thrombosis and Haemostasis</i> 6:1318, 1995.	
		Esmail et al., <i>Thrombosis and Haemostasis</i> 5:91-92, 1997.	
		Esmail et al., <i>Thrombosis and Haemostasis</i> 5:498-499, 1997.	
		Gerrard et al., <i>Thrombosis and Haemostasis</i> 6:1307, 1995.	
		Gustafsson et al., <i>Thrombosis Research</i> 101:171-181, 2001.	
		Katz et al., <i>Biochemistry</i> 34(26):8264-8280, 1995.	
		Martichonok et al., <i>J. Am. Chem. Soc.</i> 118:950-958, 1996.	
		Matt et al., <i>Bioorg. Med. Chem.</i> 8:2291-2303, 2000.	
		Matteson, <i>Chem. Rev.</i> 89:1535-1551, 1989.	
		Matteson et al., <i>J. Org. Chem.</i> 61:6047-6051, 1996.	
		Metternich et al., <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> 97:345, 1992.	
		Philipp et al., <i>The Design of Synthetic Inhibitors of Thrombin</i> 340:67-77, 1993.	
		Rewinkel et al., <i>Current Pharmaceutical Design</i> 5:1043-1075, 1999.	
		Saitoh et al., <i>Pharmaceutical Research</i> 16(11):1786-1789, 1999.	
		Sanderson et al., <i>Current Medicinal Chemistry</i> 5:289-304, 1998.	
		Skordalakes et al., <i>Biochemistry</i> 37(41):14420-14427, 1998.	
		Spencer et al., <i>Tetrahedron</i> 58:1551-1556, 2002.	
		Stahl et al., <i>Handbook of Pharmaceutical Salts Properties, Selection, and Use</i> , Verlag Helvetica Chimica Acta, Postfach, CH-8042 Zürich, Switzerland, 2002.	
↓		Tapparelli et al., <i>The Journal of Biological Chemistry</i> 268(7):4734-4741, 1993.	

EXAMINER SIGNATURE: /Brian-Yong Kwon/	DATE CONSIDERED: 07/12/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6613-66749
		Application Number	10/658,971
		Filing Date	September 9, 2003
		First Named Inventor	David Jonathan Madge
		Art Unit	1615
		Examiner Name	To be assigned
BK		Tapparelli et al., <i>Trends Pharmacol. Sci.</i> 14:366-376, 1993.	
		Trigen Limited, <i>TRI 50b Non Confidential Information</i> pp. 1-12, July 2002.	
		Trigen Limited, "Looking for a career in Biotechnology?" poster exhibited at XVIIth International Symposium on Medicinal Chemistry, Barcelona, Spain, September 5, 2002.	
		Tripathy et al., <i>Synthesis</i> pp. 200-206, 1990.	
		Wu et al., <i>Journal of Pharmaceutical Sciences</i> 89(6):758-765, June 2000.	
		Yang et al., <i>Pharmaceutical Research</i> 16(9):1331-1343, 1999.	
		Yang et al., <i>Medicinal Research Reviews</i> 23(3):346-368, 2003.	

EXAMINER SIGNATURE:	DATE CONSIDERED:
/Brian-Yong Kwon/	07/12/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6613-66749-01
Application Number	10/658,971
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1615
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
BK		5,639,739	17 June 1997	Dominguez et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee


OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
BK		Berge et al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> 66(1):1-19, 1977

EXAMINER
SIGNATURE: /Brian-Yong Kwon/

DATE
CONSIDERED: 07/12/2006

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6613-66749-01
Application Number	10/658,971
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1615
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
BK		5,169,841	08 Dec 1992	Kleeman et al.
↓		6,114,308	05 Sept 2000	Claeson et al.
↓		6,297,217	02 Oct 2001	Adams et al.
↓		6,417,174	09 July 2002	Shoichet et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
BK		Europe	EP 0 235 692	19 Feb 1987	Behringwerke Aktiengesellschaft
↓		Europe	EP 0 599 633	24 Nov 1993	Thrombosis Research Institute
↓		WIPO/PCT	WO 89/09612	19 Oct 1989	Corvas, Inc.
↓		WIPO/PCT	WO 94/21668	29 Sept 1994	The DuPont Merck Pharmaceutical Company
↓		WIPO/PCT	WO 98/00443	08 Jan 1998	Thrombosis Research Institute

EXAMINER SIGNATURE: /Brian-Yong Kwon/

DATE CONSIDERED: 07/12/2006

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.